Brian Tinkham

President, Chief Executive Officer

As an invited speaker and faculty for multiple U.S. and international gastroenterology and hepatology societies, Brian is recognized as a leader in innovation and entrepreneurship. He has held significant roles at Medtronic as Vice President of Sales and New Technologies for the GI & Hepatology division. He was the co-founder of Beacon Endoscopic (acquired by Covidien 2014) and held global marketing and sales leadership positions at Boston Scientific. 


Peter Lukin

Chief Operating Officer

Peter has over two decades of experience in new product development, operations, and general management of interventional endoscopic instruments and glucose sensors. Most recently he served as Vice President of Operations for Beacon Endoscopic (acquired by Covidien 2014). Prior, he was responsible for over 15 commercial product launches of biliary, tissue acquisition, enteral feeding and hemostasis endoscopic technologies.

Vice President, Marketing

David Karasek is a medical device marketing and sales professional with more than 16 years of experience in the field of gastrointestinal disease, with a focus on flexible endoscopy and minimally invasive surgery (MIS). During his career he has consistently held increasing roles of responsibility, most recently being the Director of Global Field Marketing at Medtronic GIH. Throughout David’s career he has been recognized as a leader in the field of devices and has led teams in support and implementation of the following:  corporate acquisitions, technology licensing, product development, product commercialization, clinical & regulatory strategies all on a global scale.


David began his medical device career in sales with GE Healthcare Ultrasound.  He earned a Bachelor of Science from the University of Wisconsin-Milwaukee in Healthcare Administration


Annette Fagnant

Clinical and Regulatory Consultant 

Ms. Fagnant has served the medical device industry for more than 30 years in both regulatory affairs and clinical research capacities. She has extensive experience in strategy, development and achieving clinical and regulatory submission approvals for a wide range of medical devices, including minimally-invasive/non-surgical therapeutic devices in the obesity and Type 2 diabetes space. Prior to consulting, Ms. Fagnant was employed by Bard/Davol for nearly ten years as Regulatory/Clinical leader at the divisional and corporate level. As a consultant, her clients have included Beacon Endoscopic, Bard/Davol, Boston Scientific/Guidant Corporation, AngioDynamics Inc., Covidien, and Johnson & Johnson.


Director of Program Management

Jeff Wallace is the Director of Program Management at GI Windows.  Leveraging 20 years of experience in medical device new product development and program management Jeff is responsible for managing the overall scope, schedules, and risk management for GI Window’s development programs.    Jeff has a proven track record in leading product development process, procedures and supply chain from start-up to large cap Medtech companies.    Prior to joining the company, Jeff has held positions of increasing responsibility at Ximedica, Teleflex, C.R. Bard, and Infinite Biomedical Technologies.  Jeff holds an undergraduate degree in bioengineering from Syracuse University and a masters degree in biomedical engineering from Johns Hopkins University.



Director of Research & Development

Mr. Seddon brings 14 years of innovation and manufacturing expertise to the research and development of next generation products for the GI Windows team.   Mr. Seddon’s experience has resulted in a deep knowledge of metallurgy and polymers.  His experience has equipped him with the ability to quickly assess and solve technical challenges.  Mr. Seddon has a unique ability to coalesce cutting edge design with highly manufacturable finished products.  These foundational knowledges are critical for GI Window’s technology growth.  His prior experiences include Putnam Plastics, Nine Point Medical and Boston Scientific Endoscopy. 

JEssica K. Musiak, MPH

Director of Clinical Affairs

Jessica brings 20 years of experience working at CROs, Pharmaceutical, Biotech, Medical Device and Consulting Firms to the GIW team.  Jessica has an extensive background in clinical affairs and project/program management at early-stage start-up to multinational corporations.  Additionally she has vast experience with strategic planning for clinical studies, including vendor selection, trial budgeting and study implementation. Jessica has overseen studies in the US, Europe, South American, India, Australia and New Zealand.  Jess holds a B.S. from Bates College and  Masters in Public Health from Boston University.


Board of directors


John Cammett 


Co-Founder Realterm Private Equity

Mr. Cammett, a lifelong entrepreneur, is the co-founder of Realterm Private Equity Fund, which now represents over $5BN in assets through five logistics-oriented equity fund series.  John now sits on the Executive Management Committee of Realterm and the Investment Committees of the Funds.

Mr. Cammett has extensive experience investing in the Life Science sector. John is the major shareholder and a board member of several MedTech & Biotech companies.  John graduated from Harvard with an AB in Engineering and Applied Sciences.


Payson Coleman, Esq 


Senior Counsel, Pillsbury
Payson is highly experienced with privately held companies, private equity and non-profits.  He offers extensive legal and investment expertise as well as broad experience and critical thinking outside of the medical device and healthcare industries to compliment the other GI Windows board members.


Andy McGibbons


Partner, Sonder Capital

Mr. McGibbon is a Managing Partner with Sonder Capital, supporting and investing in impactful healthcare startups from the ground up. Prior to his role at Sonder Capital, he worked with private and public medtech companies to accelerate innovation and translate clinical needs into viable commercial products. He also designed and implemented cross-functional innovation programs with large-cap medtech companies.


Mr. McGibbon is a former Stanford Biodesign Fellow and Ferolyn Fellow, and holds a M.Sc. in Management, Technology and Economics from ETH Zurich and a B.S. in Materials Engineering from the University of Cincinnati.


V. Kadir Kadhiresan, PhD


Vice President, Venture Investments

Johnson & Johnson Innovations

Based in Boston, Kadir works closely with Johnson & Johnson leadership to identify business needs and has responsibility for sourcing, investing and managing venture investment opportunities. He holds board seats for several JJDC portfolio companies. Some of his investments include Coherex Medical (Acquired by Biosense Webster/JNJ), Spinal Modulation (Acquired by St.Jude/ABT), Novocure (NASDAQ: NVCR), Torax Medical (Acquired by Ethicon/JNJ), Neotract (Acquired by Teleflex) and Inspire Medical Systems (NYSE: INSP).


Kadir received a PhD and MS in Biomedical Engineering from the University of Michigan, Ann Arbor, an MBA from the Kellogg School of Management at Northwestern University, and a BS in Electrical Engineering from National Institute of Technology (REC), Trichy, India.  Kadir was awarded the engineering alumni merit award from University of Michigan and serves on its biomedical engineering advisory board.


Frederic Moll, MD 


Chief Development Officer, Johnson & Johnson Healthcare 

Dr Moll brings both clinical and business expertise to augment and compliment the GI Windows board.   He is globally recognized as the Founder of Robotics in healthcare.  Prior to J&J, Dr. Moll co-founded Auris Health (acquired by J&J, $5.7B) and served as Chief Executive Officer. Earlier in his career, Dr. Moll has founded and led several Medtech companies including co-founder of Intuitive Surgical Inc. (Stock ISRG), serving as its first Chief Executive Officer. 


David Neustaedter, Ph.D 


Vice President of Venture Capital, Medtronic

Working closely with Medtronic leadership, David has completed new venture capital investments in areas of strategic interest and has socialized key developments at existing portfolio companies. During his career, he has completed many successful investments. He has served as a Director or Observer on approximately 20 Boards including superDimension, Idev, Medina, and Entellus. He received his Ph.D. in molecular biology from the University of British Columbia, an MBA from Yale University, and completed post-doctoral fellowships at the Mount Sinai School of Medicine.


Peter Rogal 


CEO, Gold Circuit Electronics Global Sales and Services LLC
Peter has over 40 years of experience in the high tech electronics industry and as a serial entrepreneur and business executive.  He has invested and maintains board seats in several rapidly growing Lifescience companies.  He is the founder and 100% shareholder of Brooktrout Ventures, a small to midsized angel investing firm.


Christopher Thompson, MD 


Professor of Medicine, Harvard Medical School and Director of Endoscopy & PI of the Developmental Endoscopy Lab at Brigham and Women’s Hospital, Harvard Medical School.  

Dr. Thompson is the co-founder of Beacon Endoscopic and GI Windows.  He is one of the seminal international thought leaders in the rapidly emerging new fields of Natural Orifice Transluminal Endoscopic Surgery (NOTES) and Bariatric Endoscopy.  


Dr. Thompson received his MD degree from Pennsylvania State University College of Medicine and completed advanced Clinical and Research fellowships at Harvard Medical School.